Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Integrated Care for the Diabetic Patient: How to Diagnose and Manage the At-Risk Patient – Part 2

By: Mark Dunbar, OD; Steven G. Ferrucci, MD; Jay M. Haynie, OD, FAAO

Webinar Credits: 1

It remains clear that although diabetes is a systemic disorder, the manifestations of diabetic complications will occur without optimal glycemic and blood pressure control. Optometrists can help continually reinforce that message by educating patients about the necessity for ongoing and yearly dilated eye exams, and discussing the potential treatments should vision loss become obvious.

The target audience for this CE Activity is Optometrists.

Expiration Date: Sunday, October 20, 2019
Release Date: October 28, 2016

Learning Objectives

This educational activity consists of a supplement and twenty (20) study questions. To obtain credit, the participant should read the Learning Objectives contained at the beginning of this activity, read the material, answer all questions in the Post Test, and complete the Activity Evaluation Form. This educational activity should take a maximum of 2.0 hours to complete.

After successfully completing this activity, optometrists will have improved their ability to:

  • Determine who is a high-risk patient for the onset of diabetic eye disease
  • Discuss the importance of conducting yearly dilated exams on diabetic patients
  • Develop plans to initiate co-management of the diabetic patient with both ophthalmologists and primary care physicians/endocrinologists
  • Implement strategies to educate patients on the ocular manifestations of diabetes

Accreditation and Designation Statement

This course is COPE approved for 1.0 hour(s)of CE Credit for Optometrists

COPE Course ID: 51337-SD

COPE Event ID: 112389

 

Faculty and Disclosures

Mark Dunbar, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Carl Zeiss Meditec and Regeneron Pharmaceuticals Inc.

Paul Chous, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bausch & Lomb Incorporated; CooperVision; Freedom Meditech, Inc.; Regeneron Pharmaceuticals Inc.; and ZeaVision, LLC and Grant/Research Support: ZeaVision, LLC

Steven Ferrucci, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; CenterVue; Macula Risk; and Maculogix Inc,

Jay Haynie, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: ArticDx Inc.; Carl Zeiss Meditec, Inc. Reichert, Inc.; Notal Vision, Ltd.; and ThromboGenics NV.

Leo Semes, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Optovue, Inc.; and Regeneron Pharmaceuticals Inc. and Stock/Shareholder: HPO

Cheryl Cavanaugh, MS; Michelle Dalton and Melanie Lawler, PhD have no relevant commercial interests to disclose.

 

Disclosure Attestation

Each of the contributing physicians listed above has attested to the following: 1. that the relationships/affiliations noted will not bias or otherwise influence his or her involvement in this activity; 2. that practice recommendations given relevant to the companies with whom he or she has relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and 3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

 

Product Usage in Accordance with Labeling

Please refer to the official product information for each product for discussion of approved indications, contraindications and warnings.

 

Grantor Statement

This COPE CE Activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals Inc.

 

 

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, The University of Houston, Regeneron Pharmaceuticals Inc., or Advanced Ocular Care.

 

Pretest

Integrated Care for the Diabetic Patient: How to Diagnose and Manage the At-Risk Patient: Webinar

Mark Dunbar, OD; Steven G. Ferrucci, OD; Jay M. Haynie, OD, FAAO

Test

Instructions

Back